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1. Introduction
Tissue or cell injuries and assorted infections are targets to major studies on 
inflammation. These conditions play a central role for the understanding of the 
inflammatory mechanism as a pathophysiological process. In addition, tissue-
resident macrophages can create an adaptive response against stressed or unwell 
environments, which may lead to various pro-inflammatory pathways. Together, 
these conditions may be associated with a broad spectrum of acute and chronic 
inflammation in some of contemporary human disorders [1].
In general, inflammation is a natural response to avoid the progress from fester 
to deadly in any kind of injury. Its very well-balanced network of anti- and pro-fac-
tors should be constantly checked by the immune system to make sure the healing 
process does not miss your goal and becomes unreliable to the point of creating an 
incorrigible damage [1, 2].
Regardless of its etiology, patients suffering from inflammatory episodes or 
disorders have higher risk of facing other clinical complications. Acute and chronic 
inflammations have their particular dynamics and prognostics but, even if it is 
unclear in several aspects, it has been pertinent in addressing any analysis on 
inflammation under a translational approach.
In face of that, the following review is a summary report on essential aspects 
related to inflammation as a biological event, considering the potentially wide range 
of questions and action lines, from its molecular basis to some potential clinical 
outcomes.
2. Causes and early stages of inflammation
Different agents can promote inflammatory events, such as (a) necrosis, due 
to the decrease in blood flow and lack of nutrients and oxygen in the target tissue, 
which results in tissue death; (b) chemical or physical traumas, like radiation, 
burn, frostbite, corrosion by oxidizing, alkalis, or acid; (c) displaced or delayed 
immunological response due to genetic conditions or unstable metabolism; and 
(d) infections or coexistent microbiome unbalanced status, mainly from very 
common performers as bacteria, through endotoxins release, and virus, which 
encroach cells for its proliferation until the host wrecking [2–6].
Basic signs of inflammation are (1) edema or swelling caused by gradual 
deposit of fluid outside of blood vessels; (2) pain, caused by mechanical action 
of edema and/or direct response to prostaglandin, serotonin, and bradykinin 
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reactions; (3) redness, as a consequence of vasodilation at damage site; and (4) 
fever caused by pro-inflammatory mediators that contribute to the rise of local 
and/or systemic temperature [1, 2].
Vasoconstriction, the constriction of blood vessels, which increases blood pres-
sure, is one of the first and brief reactions to inflammatory process. In the begin-
ning of inflammatory process, it is followed by a counterreaction, the vasodilation. 
During vasodilation the blood flow increases into the target area, and it can take 
from few minutes to long-time periods to be released. These contractile events on 
the vessel affect the blood flow and, for consequence, the blood vessel wall perme-
ability. When the vessel wall becomes more permeable, the transit of fluids also is 
raised, beyond usual salt- and water-based liquids [7].
A protein-rich fluid, the exudate, increases its transposition through the wall, 
which affects the distribution of anti-inflammatory elements, as coagulation factors 
and antibodies, in the sense to refrain the spreading of infectious agents.
3. Cellular setup and molecular mediators
The inflammatory environment with fluid leaking out the blood vessels creates 
the conditions for white cell adhesion to the blood vessel wall since the blood flow 
starts to slowdown. This is the initial step of a serial process moving out the white 
cells from the vessel lumen to the interstitium of the damaged tissue.
Two major aspects related to the body’s reaction to inflammation are the speed and 
the amount of white cells taken to the target tissue. Phagocytes are the predominant 
form of leukocytes designated to clean up the site of injury, eating bacteria and strange 
elements, removing the cellular remains produced during the injury progress [2].
Neutrophils are a class of white cells involved in acute inflammation. This par-
ticular type of phagocyte holds granules of enzymes capable of destroying toxic 
substances, such as reactive oxygen species, proteins, and cells, making these cells the 
major components in the injury processing. For local and weak damages, the amount 
of circulating neutrophils is enough for inflammatory response. However, for wide 
damages, sources of neutrophils from the bone marrow are constantly requested for 
acting on the injured site as the early agents. Even if in its immature form, neutrophils 
can reach the local spot quickly after the inflammatory process starts [2].
Monocytes are the second group of blood cells requested for acting on the 
inflamed area, usually several hours after the beginning of this process. These 
white blood cells when matured are called macrophages, and they are responsible 
for the ultimate step of engulfing and disposing the invasive cells and foreign ele-
ments. Macrophages are also the predominant agents in the chronic inflammation 
healing [1–2].
The cells required to act at the site of inflammation actually move from blood 
vessels to injured tissue. Both neutrophils and macrophages use chemical recogni-
tion properties, called chemotaxis, to guide themselves through the pathway. 
While the lesion itself has an important role in the inflammation healing initiation, 
chemotaxis is responsible for determining how far fast and effective will be its 
processing. It is a complex network working from the chemical signals given out by 
the injured tissue. Structural compounds, such as endothelial cells, operate together 
with blood plasma elements, platelets, and mast cells, creating a chemical commu-
nications to address the differentiated white blood cells to the right site, according 
to each role and time frame [8, 9].
The blood plasma is an important source of inflammatory mediators. Some 
complex proteins are connected through its elaborate cascade pathways, such as the 
complement, coagulation factors, the fibrinolytic system, and the kinins.
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Activated complement proteins, for example, are able to increase vascular 
permeability, make mast cells release histamine, and work for neutrophils as 
chemotactic elements.
On the other hand, the vascular permeability is directly influenced by a serial 
process among the coagulation, fibrinolytic, and kinin systems. Coagulation, in 
a cascade of activations, contributes to fluid exudate formation, polymerizing 
fibrinogen to fibrin, which is part of the exudate. Fibrin, in its turn, is quickly 
broken by the plasmin produced from fibrinolytic system, resulting in chemical 
compounds that interfere with the permeability of blood vessels. Overlapping these 
events, the kinin system also generates mediators responsible to increase vascular 
permeability. Moreover, an essential kinin named bradykinin is in charge of two of 
the main uncomfortable effects of inflammation, itching and pain.
Prostaglandins are considered major inflammatory mediators. This type of fatty 
acids plays an essential role on the platelet cluster formation, also interfering on 
clotting process. Some prostaglandins can promote vascular permeability too. This 
group of molecules is targeted for many anti-inflammatory drugs, since they are 
related to fever and pain caused by inflammation [10, 11].
Another group of inflammatory mediators, including histamine, cytokines, and 
lysosomal compounds, has a significant role on the capacity to exchange the perme-
ability of vessels, even with its distinct characteristics. Histamines, for example, 
are the first line of agents released to increases vascular permeability, since they 
are easily accessed from mast cells and basophils. The activation of histamine H1 
receptors promptly changes some pro-inflammatory pathways. Moreover, the 
histamine regulates the synthesis of cytokine in some inflammation process, such 
as allergies. In turn, cytokines released by different cells exhibit features that affect 
vessel dilatation and the ability to chemically transport white blood cells through 
the blood vessel into the interstitium of injured parenchyma [7].
Closing this overview, it is important to highlight that the time of inflammation 
processing is the key to distinguish an acute response, which usually takes a couple 
of days, from a chronic inflammation, which trends to request long time for healing 
and its outcomes may persist. From autoimmune diseases to long-term inflamma-
tory sequels, many different targets may be addressed in classic inflammatory path-
way, alternative networks, and its upshots. From microbiome interactions, richly 
reported in recent studies [3–6], to chronic side effects of traditional or innovative 
treatments, many therapeutics targets have being studied to develop new inflam-
mation mediators that could be helpful, either in scientific or clinical decisions.
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